# RP-6306 in Patients With Advanced Cancer

Source: https://onco.cc/trials/nct05605509/  
OnCo record `nct05605509` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Lunresertib run by Canadian Cancer Trials Group, completed.

## Summary

RP-6306 in Patients With Advanced Cancer is a phase 2 interventional study registered as NCT05605509 by Canadian Cancer Trials Group, with 28 participants enrolled, started 2023-05-24. Conditions recorded: Advanced Cancer. Interventions recorded: RP-6306, Gemcitabine, FOLFIRI Protocol, Trastuzumab and RP-3500.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05605509
- Phase: 2
- Setting: A Phase II Study of RP-6306 in Patients With Advanced Cancer
- Sponsor: Canadian Cancer Trials Group
- Enrolled: 28

## Sources

- ClinicalTrials.gov NCT05605509: https://clinicaltrials.gov/study/NCT05605509

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Lunresertib](https://onco.cc/drugs/lunresertib/)
- companies: [Debiopharm](https://onco.cc/companies/debiopharm/), [Repare Therapeutics](https://onco.cc/companies/repare-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05605509.json